GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments

GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel

GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France

GenSight Biologics Announces Regulatory Approval for GS010/LUMEVOQ® REVISE Dose-Ranging Study in France

GenSight Biologics announces regulatory authorizations for Individual Patient Expanded Access treatment with GS010/LUMEVOQ® in the US

GenSight Biologics Reports Interim Financial Results for the First Half of 2025

GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France

GenSight Biologics Announces the Filing of its 2024 Universal Registration Document

GenSight Biologics Reports End-of-Year Cash Position and Provides Business Update

GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation